BRIEF published on 11/27/2025 at 00:20, 8 days 5 hours ago Transgene: Resumption of Trading on Euronext Paris Euronext Paris Biotechnology Capital Increase Transgene Quoting
PRESS RELEASE published on 11/27/2025 at 00:15, 8 days 5 hours ago Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets Transgene resumes trading of shares on Euronext Paris following capital increase results publication Euronext Paris Shares Trading Capital Increase Transgene
BRIEF published on 11/26/2025 at 23:37, 8 days 5 hours ago Transgene Raises €105 Million for Cancer Vaccine Development Biotechnology Fundraising Cancer Vaccines Transgene Myvac® Platform
PRESS RELEASE published on 11/26/2025 at 23:32, 8 days 5 hours ago Transgene Successfully Completes a Fundraising of c. €105 Million Transgene successfully completes a fundraising of c. €105 million, enabling acceleration of myvac® program development and extending financial visibility until early 2028 Fundraising Cancer Vaccines Transgene Financial Visibility Myvac® Program
BRIEF published on 11/25/2025 at 22:06, 9 days 7 hours ago Transgene raises funds with the Talisman project Euronext Paris Fundraising Transgene Talisman Myvac®
BRIEF published on 11/25/2025 at 21:47, 9 days 7 hours ago Temporary suspension of trading in Transgene shares Euronext Paris Biotechnology Capital Increase Transgene Quoting
PRESS RELEASE published on 11/25/2025 at 21:42, 9 days 7 hours ago Correction: Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris Transgene requests temporary suspension of trading on Euronext Paris pending capital increase results. Trading to resume on November 27, 2025 Euronext Paris Trading Capital Increase Suspension Transgene
BRIEF published on 11/25/2025 at 20:46, 9 days 8 hours ago Temporary Suspension of Trading in Transgene Shares on Euronext Paris Euronext Paris Biotechnology Capital Increase Transgene Trading Suspended
PRESS RELEASE published on 11/25/2025 at 20:41, 9 days 8 hours ago Transgene Announces the Temporary Suspension of Trading of its Shares on Euronext Paris Transgene requests temporary suspension of trading on Euronext Paris pending capital increase results Euronext Paris Trading Capital Increase Suspension Transgene
BRIEF published on 11/25/2025 at 19:20, 9 days 10 hours ago Transgene Launches €105 Million Fundraising Initiative Biotechnology Investment Transgene Fundraising Myvac® Program Cancer Vaccine Development Institutional And Retail Offerings
Published on 12/05/2025 at 02:35, 2 hours 52 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 4 hours 27 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 22 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 27 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 56 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 36 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 1 minute ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 12 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 16 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 11 hours 27 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 42 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 43 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 26 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago Declaration of voting rights at the end of November 2025
